Medicus Pharma Ltd (MDCX) Stock Price, Quote & News

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to M...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 610 540 7515

Website: medicuspharma.com

Address:

300 Conshohocken State Road, Suite 200, Conshohocken, United States

2TrustHim Feb. 23 at 4:29 PM

$MDCX Interesting Volume And Price Spikes. Seems Like Something Has A Higher Interest Event About To Happen!!!

1 · Reply

BioAB Feb. 20 at 2:12 AM

$CLVSQ anyone buying into Pats new company $MDCX ?

0 · Reply

VolatilityDispersion Feb. 17 at 1:04 PM

$MDCX Obscure micro-cap; minimal information.

0 · Reply

KnightHawks Feb. 16 at 5:46 AM

$MDCX The FDA cleared the company to begin a Phase 2b trial for Teverelix, targeting advanced prostate cancer patients with high cardiovascular risk. This study will focus on dose optimization in 40 patients. $XTIA Bullish 2026 Guidance: During a shareholder town hall on February 5, 2026, the company projected full-year revenue to exceed $160 million (representing ~30% growth). They also expect to reach a positive monthly cash flow of nearly $2 million by the end of 2026.

0 · Reply

OfficialStocktwitsUser Feb. 13 at 2:40 PM

$MDCX RSI: 32.14, MACD: -0.1414 Vol: 0.13, MA20: 1.18, MA50: 1.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

2TrustHim Feb. 13 at 1:12 PM

$MDCX https://youtube.com/watch?v=tuSCHHlwqwg&si=3frmeX3GJ1wX4FvY

0 · Reply

2TrustHim Feb. 12 at 1:41 PM

$MDCX https://youtu.be/2-naOb7uJRc?si=eumsbejKNkAdQ62G

0 · Reply

2TrustHim Feb. 11 at 4:52 PM

$MDCX AI Overview Based on recent updates, Medicus Pharma is actively progressing its "SkinJect" clinical development (SKNJCT-003 and SKNJCT-004), with interim data already showing positive trends as of March 2025. Key Phase 2 clinical data readouts are approaching as of early 2026, with potential for, or, this YouTube video indicates, potentially early as 2026 for, a commercially available product for equine and other applications. Key Details on Data and Timelines: Interim Results: A March 2025 analysis of the SKNJCT-003 study indicated >60% clinical clearance in patients. Upcoming Data: As of January 2026, Medicus is approaching further Phase 2 clinical data readouts, highlighting 2026 as a critical year for these results. Clinical Studies: The company is currently running studies (SKNJCT-003 in the US and SKNJCT-004 in the UAE) focusing on non-invasive treatment.

1 · Reply

2TrustHim Feb. 11 at 4:49 PM

0 · Reply

WeedMan5000 Feb. 11 at 3:03 PM

$MDCX Hitting new 52 week low cause I bought, sorry guys! This happened 3 times in 2025 and already off to a bad start in 2026 with this one

1 · Reply

Medicus Pharma on Bloomberg World

Feb 10, 2026, 7:30 AM EST - 13 days ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Jan 23, 2026, 7:30 AM EST - 4 weeks ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 22, 2026, 7:30 AM EST - 4 weeks ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 20, 2026, 7:30 AM EST - 4 weeks ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 12, 2026, 7:30 AM EST - 6 weeks ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 5, 2026, 7:30 AM EST - 7 weeks ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Dec 22, 2025, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 15, 2025, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 5, 2025, 3:20 PM EST - 2 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 1, 2025, 8:00 AM EST - 3 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Nov 24, 2025, 8:00 AM EST - 3 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 17, 2025, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 14, 2025, 5:00 PM EST - 3 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 13, 2025, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 29, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 22, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 14, 2025, 8:07 AM EDT - 4 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 13, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Sep 29, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 24, 2025, 9:26 AM EDT - 5 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 18, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 8, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 2, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Aug 21, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 4, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Jul 23, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 21, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 8, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 4, 2025, 9:49 AM EDT - 8 months ago

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Jun 30, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 23, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 12, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 9, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 2, 2025, 1:40 PM EDT - 9 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 9 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 22, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 12, 2025, 2:20 PM EDT - 10 months ago

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

Apr 28, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Apr 21, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Mar 6, 2025, 8:30 PM EST - 1 year ago

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Mar 6, 2025, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 27, 2025, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 11, 2025, 7:41 AM EST - 1 year ago

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Dec 12, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Dec 2, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

2TrustHim Feb. 23 at 4:29 PM

$MDCX Interesting Volume And Price Spikes. Seems Like Something Has A Higher Interest Event About To Happen!!!

1 · Reply

BioAB Feb. 20 at 2:12 AM

$CLVSQ anyone buying into Pats new company $MDCX ?

0 · Reply

VolatilityDispersion Feb. 17 at 1:04 PM

$MDCX Obscure micro-cap; minimal information.

0 · Reply

KnightHawks Feb. 16 at 5:46 AM

0 · Reply

OfficialStocktwitsUser Feb. 13 at 2:40 PM

0 · Reply

2TrustHim Feb. 13 at 1:12 PM

$MDCX https://youtube.com/watch?v=tuSCHHlwqwg&si=3frmeX3GJ1wX4FvY

0 · Reply

2TrustHim Feb. 12 at 1:41 PM

$MDCX https://youtu.be/2-naOb7uJRc?si=eumsbejKNkAdQ62G

0 · Reply

2TrustHim Feb. 11 at 4:52 PM

1 · Reply

2TrustHim Feb. 11 at 4:49 PM

0 · Reply

WeedMan5000 Feb. 11 at 3:03 PM

$MDCX Hitting new 52 week low cause I bought, sorry guys! This happened 3 times in 2025 and already off to a bad start in 2026 with this one

1 · Reply

2TrustHim Feb. 10 at 7:18 PM

$HURA $MDCX These Two Are Interesting!!!

0 · Reply

FlyerUp Feb. 10 at 4:00 PM

$MDCX get past 1.35 and go to 1.70s

0 · Reply

allyboy Feb. 10 at 3:31 PM

$JZXN typical...moving to $MDCX

0 · Reply

allyboy Feb. 10 at 3:06 PM

$ABP buy the dips....$MDCX good news

0 · Reply

FlyerUp Feb. 10 at 2:56 PM

$MDCX low float, great news,

0 · Reply

FlyerUp Feb. 10 at 2:42 PM

$MDCX Good News

0 · Reply

2TrustHim Feb. 10 at 12:55 PM

$MDCX When Do We Get Skinjet Update?

1 · Reply

2TrustHim Feb. 10 at 12:35 PM

$MDCX We Have A Little Life. Proceeding Is Good News.

1 · Reply

BigPennyStockAlerts Feb. 10 at 12:33 PM

$MDCX- $1.21 Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

0 · Reply

MokshaMoney Feb. 9 at 3:04 PM

$MDCX Medical diagnostics; requires broad reimbursement for tests.

0 · Reply

2TrustHim Feb. 5 at 8:04 PM

$MDCX Is This Finally dead?

1 · Reply

NVDAMillionaire Feb. 4 at 6:26 AM

$MDCX Great piece that accurately captures MDCX's current position. So if you want to refresh your understanding of MDCX or learn about MDCX for the first time, this is essential reading. https://everyticker.com/quote/MDCX/analysis/clinical-promise-meets-financial-peril-at-medicus-pharma-nasdaq-mdcx

0 · Reply

Market Cap	30.15M
Revenue (ttm)	0.00
Net Income (ttm)	-11.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	738,500
Avg Vol	369,760
Day's Range	N/A - N/A
Shares Out	25.55M
Stochastic %K	56%
Beta	-1.17
Analysts	Strong Sell
Price Target	$19.67